Key result
LVNC stems from arrested endomyocardial morphogenesis and requires management via risk stratification and medical therapy.
Left ventricular noncompaction cardiomyopathy is a condition of arrested endomyocardial morphogenesis diagnosed via imaging and managed primarily with medical therapy and risk stratification.
Risk stratification guides LVNC care; leaves open prospective validation of diagnostic criteria.
Left ventricular noncompaction cardiomyopathy (LVNC) is a disease associated with ventricular hyper-trabeculation. LVNC occurs due to the arrested development of endomyocardial morphogenesis. On imaging using echocardiography and cardiac MRI, the pathology results in a 2-layered myocardium consisting of a thin epicardial compacted layer and a thicker noncompacted endocardial layer. The primary goal of imaging is to ascertain the presence of other structural cardiac abnormalities and calculate the ratio of the noncompacted to compacted layer to confirm LVNC. This disease in patients can be asymptomatic or lead to, most commonly, heart failure, arrhythmias, and thromboembolism. While surgical measures, including transplantation, can be curative in advanced disease, LVNC is primarily managed with risk stratification and further medical management.
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2026) conducted a review in Left ventricular noncompaction cardiomyopathy (LVNC). Left ventricular noncompaction cardiomyopathy is a disease of arrested endomyocardial morphogenesis characterized by a 2-layered myocardium, managed primarily with risk stratification and medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: